By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Cannabis NewsCannabis News
Aa
  • Cannabis
  • CBD
  • Science
  • Culture & Arts
  • Cannabis Press Releases
  • More
    • About Maryjanes Post
    • Cannabis Advertising
    • Cannabis Partnerships
Reading: Anebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
Share
Aa
Cannabis NewsCannabis News
Search
  • Topics
    • Business
    • Cannabis
    • Cannabis Tech
    • Culture & Arts
    • Industry Leaders
    • Cannabis Press Releases
  • Topics
    • Business
    • Cannabis
    • Cannabis Tech
    • Culture & Arts
    • Industry Leaders
    • Cannabis Press Releases
  • About Maryjanes Post
    • Ambassador
    • Cannabis Partnerships
Follow US
  • Ad Choices
  • RSS Terms of Service
© 2018 - 2022 MaryJanes Post Media. All Rights Reserved.
Cannabis News > Cannabis Press Releases > Anebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
Cannabis Press Releases

Anebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

Business Wire
Business Wire January 6, 2022
Updated 2022/05/30 at 7:51 AM
Share
SHARE

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announces that management will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022. A webcast of the presentation will be available on-demand beginning January 10, 2022 at 7:00 a.m. Eastern time on the Investors section of Anebulo’s website.

About Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of acute cannabinoid intoxication within one hour of administration. ANEB-001 is a competitive antagonist at the human cannabinoid receptor type 1 (CB1) with good oral bioavailability and brain penetration (rat brain:plasma ratio of approximately 1.5). Clinical trials completed to date have shown that ANEB-001 is rapidly absorbed, well tolerated, and may lead to weight loss, an effect that is consistent with CB1 antagonism in the central nervous system. For further information about Anebulo, please visit www.anebulo.com.

Contacts

- Advertisement -

Anebulo Pharmaceuticals, Inc.
Scott Anderson

Head of Investor Relations and Public Relations

(858) 229-7063

[email protected]

Rex Merchant

Chief Financial Officer

(512) 598-0931

[email protected]

You Might Also Like

Virpax Will Pursue Direct to OTC Pathway for Epoladerm™ for Pain Associated with Osteoarthritis

WM Technology, Inc. Joins Russell 3000®, Russell 2000® and Russell Microcap® Indexes

Leafly Set to Join Russell 3000® and Russell 2000® Index

Proposed Settlement Reached in 2016 Class Action

Akanda Announces Changes to Board of Directors and Postponement of Annual General Meeting

TAGGED: Business Wire
Business Wire January 6, 2022
Share this Article
Twitter Reddit Email Copy Link
Previous Article Canopy Growth Issues Environmental, Social, and Governance Report
Next Article Flora Growth Appoints Industry Authority Tim Leslie as Chairman of Its Newly Formed Advisory Board

You Might Also Like

Virpax Will Pursue Direct to OTC Pathway for Epoladerm™ for Pain Associated with Osteoarthritis

June 27, 2022

WM Technology, Inc. Joins Russell 3000®, Russell 2000® and Russell Microcap® Indexes

June 27, 2022

Leafly Set to Join Russell 3000® and Russell 2000® Index

June 24, 2022

Proposed Settlement Reached in 2016 Class Action

June 24, 2022

Cannabis News and More

Work with an experienced cannabis media firm to provide your brand with the exposure it needs.

Cannabis Topics

  • Cannabis
  • Business
  • CBD
  • Cannabis Science
  • Culture & Arts

Company

  • About Maryjanes Post
  • Contact Cannabis Media
  • Contributor Guidelines

Terms of Use

  • TERMS
  • PRIVACY
  • CONTRIBUTOR AGREEMENT
  • DMCA

Resources

  • Write For UsNew
  • Cannabis Advertising
  • Cannabis Partnerships
  • Cannabis Press ReleaseNew
Cannabis NewsCannabis News
Follow US

© 2018 - 2022 MaryJanes Post Media. All Rights Reserved.

Go to mobile version
Welcome Back!

Sign in to your account

Lost your password?